Literature DB >> 18487510

BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells.

Anna Guarini1, Sabina Chiaretti, Simona Tavolaro, Roberta Maggio, Nadia Peragine, Franca Citarella, Maria Rosaria Ricciardi, Simona Santangelo, Marilisa Marinelli, Maria Stefania De Propris, Monica Messina, Francesca Romana Mauro, Ilaria Del Giudice, Robert Foà.   

Abstract

Chronic lymphocytic leukemia (CLL) patients exhibit a variable clinical course. To investigate the association between clinicobiologic features and responsiveness of CLL cells to anti-IgM stimulation, we evaluated gene expression changes and modifications in cell-cycle distribution, proliferation, and apoptosis of IgV(H) mutated (M) and unmutated (UM) samples upon BCR cross-linking. Unsupervised analysis highlighted a different response profile to BCR stimulation between UM and M samples. Supervised analysis identified several genes modulated exclusively in the UM cases upon BCR cross-linking. Functional gene groups, including signal transduction, transcription, cell-cycle regulation, and cytoskeleton organization, were up-regulated upon stimulation in UM cases. Cell-cycle and proliferation analyses confirmed that IgM cross-linking induced a significant progression into the G(1) phase and a moderate increase of proliferative activity exclusively in UM patients. Moreover, we observed only a small reduction in the percentage of subG(0/1) cells, without changes in apoptosis, in UM cases; contrariwise, a significant increase of apoptotic levels was observed in stimulated cells from M cases. These results document that a differential genotypic and functional response to BCR ligation between IgV(H) M and UM cases is operational in CLL, indicating that response to antigenic stimulation plays a pivotal role in disease progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487510     DOI: 10.1182/blood-2007-12-127688

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.

Authors:  Ilaria Del Giudice; Davide Rossi; Sabina Chiaretti; Marilisa Marinelli; Simona Tavolaro; Sara Gabrielli; Luca Laurenti; Roberto Marasca; Silvia Rasi; Marco Fangazio; Anna Guarini; Gianluca Gaidano; Robin Foà
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

2.  Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

3.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

4.  Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Authors:  Katherine I Lin; Constantine S Tam; Michael J Keating; William G Wierda; Susan O'Brien; Susan Lerner; Kevin R Coombes; Ellen Schlette; Alessandra Ferrajoli; Lynn L Barron; Thomas J Kipps; Laura Rassenti; Stefan Faderl; Hagop Kantarjian; Lynne V Abruzzo
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

Review 5.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jennifer R Brown
Journal:  Leuk Lymphoma       Date:  2012-12

6.  Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).

Authors:  V M Patel; K Balakrishnan; M Douglas; T Tibbitts; E Y Xu; J L Kutok; M Ayers; A Sarkar; R Guerrieri; W G Wierda; S O'Brien; N Jain; H M Stern; V Gandhi
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

7.  Metadherin contribute to BCR signaling in chronic lymphocytic leukemia.

Authors:  Pei-Pei Li; Qing-Min Yao; Hui Zhou; Li-Li Feng; Xue-Ling Ge; Xiao Lv; Na Chen; Kang Lu; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

8.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Nicole Weit; Nils Lilienthal; Michael Hallek; Michael J Keating; Dan Jones
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

Review 9.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

10.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.